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Background: Non-steroidal anti-inflammatory drugs (NSAIDs) are reported to be the second most common cause
of drug hypersensitivity. In 2011, experts from the EAACI/ENDA group and GA2LEN proposed a new classification
system for NSAID hypersensitivity. The aim of this study was to classify a patient cohort with a history of NSAID
hypersensitivity according to this system.
Methods: Patients with a clinical history of NSAID hypersensitivity referred to the Allergy Centre, Odense University
Hospital between 2002 and 2011 and evaluated with oral provocation tests (OPTs) were included in the study.
Medical records were retrospectively investigated with respect to the culprit NSAID(s), underlying diseases and
symptoms at the primary reaction and during oral provocation tests (OPTs). Data was supplemented with a
questionnaire. Classification according to EAACI guideline was based on these findings.
Results: In total 149 patients were included. Of those, 39 patients (26.2%) had a positive OPT. Twenty-nine patients
were classified as cross-reactive responders and 9 patients as single NSAID responders after positive OPTs with the
culprit NSAID, but not to acetylsalicylic acid. All single NSAID responders reacted to non-pyrazolone drugs. Only one
patient could not be classified according to the EAACI/ENDA system. An overlap between respiratory and
cutaneous symptoms was found in 15/39 (38%) of patients.
Conclusions: All but one of our patients could be classified according to the EAACI classification system. Overlaps
between different classes may occur much more commonly than expected.
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Non-steroidal anti-inflammatory drugs (NSAIDs) are
among the most frequently prescribed classes of drugs
and hypersensitivity to NSAIDs is reported to be the
second most common cause of drug hypersensitivity [1].
Aspirin hypersensitivity alone is estimated to affect
0.3%-2.5% of the general population [2,3]. However, the
prevalence of NSAID hypersensitivity among patients
with underlying diseases such as asthma and chronic ur-
ticaria is much higher, affecting up to 25% and 30% re-
spectively [4,5].* Correspondence: Charlotte.moertz@rsyd.dk
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unless otherwise stated.Several subtypes of NSAID hypersensitivity have been
described depending on symptoms (respiratory, cutane-
ous, anaphylaxis), timing (immediate, delayed), under-
lying chronic diseases (asthma, chronic urticaria) or the
possible mechanism of the reaction (allergic, non-
allergic) [6-8]. Subsequently, attempts have been made
to classify NSAID hypersensitivity reactions based on
clinical history and results of drug provocation tests
[9,10]. However, until recently no uniform definition or
classification of NSAID hypersensitivity had been pro-
posed. This changed in 2011 where experts from the
EAACI/ENDA group and GA2LEN proposed a new clas-
sification system for NSAID hypersensitivity launching
guidelines on diagnostic work-up and management [11].
In 2013, the authors proposed further unification of this
classification and a revised nomenclature as well asThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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system is based on knowledge about type of reaction,
clinical manifestation, timing of the reaction, underlying
diseases, cross-reactivity and putative mechanisms.
A detailed clinical history is essential when planning
the diagnostic work-up. However, to confirm the diagno-
sis NSAID hypersensitivity an oral challenge test is
needed when taking test indications, contraindications
and security aspects into account. In vivo and in vitro
tests are not currently recommended as a routine prac-
tise except for the non-cross reactive IgE mediated reac-
tions [12].
During the last 10 years we have evaluated consecutive
patients referred with suspicion of NSAID hypersensitiv-
ity with standardized challenge tests. We used the re-
sults of the challenge tests and our knowledge about the
patients’ clinical history to classify the patients with
NSAID hypersensitivity according to the EAACI/ENDA
guideline. This is the first study from the northern part
of Europe classifying NSAID hypersensitivity in a stan-
dardized way based on history, clinical examination, oral
challenge and questionnaire data.
Methods
Patient selection
Patients with a clinical history of NSAID hypersensitivity
referred to the Allergy Centre, Odense University
Hospital, Denmark, between 2002 and 2011 were retro-
spectively identified from our database. Patients where
diagnostic work-up suggested acute cutaneous, respira-
tory and/or anaphylactic reactions in relation to NSAID
intake were referred to an oral provocation test (OPT)
and included in the study. None of the included patients
had a history of severe cutaneous adverse drug reactions
(SCARs). Patients with an isolated reaction to paraceta-
mol were not included.
Medical records and questionnaire
Medical records of the included patients were investi-
gated with regards to the culprit NSAID(s). Symptoms
at the primary reaction and during OPTs were analysed.
Anaphylaxis was defined as a rapidly evolving reaction
involving multiple organs in accordance to Simons [13]
and the severity was graded according to Sampson [14].
Data on underlying chronic urticaria, angioedema,
asthma, nasal polyposis and chronic rhinosinusitis (CRS)
were collected from the medical records. Furthermore, a
modified version of the questionnaire used in the
GA2LEN survey was sent by post to the patients [15].
This questionnaire covers a wide range of questions
concerning asthma, chronic rhinosinusitis and allergic
rhinitis. In addition to the existing questions we added
the following questions: “Have your doctor ever told you
that you have enlarged nasal polyps?” and “Have youever had nasal polyps removed?” Questionnaire surveys
are exempted from notification of the Danish Ethical
Committees Act §8 paragraph 3.
In concordance with the GA2LEN survey, asthma was
defined as reporting having ever had asthma AND at least
one of the following symptoms in the last 12 months (i)
wheeze or whistling in the chest (ii) waking up with chest
tightness (iii) waking up with shortness of breath and (iv)
waking up with an attack of cough.
Chronic rhinosinusitis was defined following the
EP3OS criteria: Presence of at least two of the following
symptoms for at least 12 weeks in the past year: (i) nasal
blockage, (ii) nasal discharge, (iii) facial pain or pressure
or (iv) reduction in sense of smell with at least one of
the symptoms being nasal blockage or nasal discharge.
Oral provocation test (OPT)
Included patients performed a primary OPT with acetyl-
salicylic acid (ASA). If the OPT was positive no further
challenges were performed. If the OPT was negative the
patient was offered an OPT with the culprit NSAID. All
OPTs were performed as open challenges under ana-
phylaxis surveillance after informed consent of the
patient. During provocation with ASA and naproxen
the following dosages were given orally with 30-minute
intervals (5 mg, 25 mg, 125 and 500 mg) adding up to
a cumulative dosage of 655 mg. Ibuprofen and diclofe-
nac were also administered with 30-minute intervals
but in different dosages, ibuprofen (5 mg, 25 mg,
125 mg and 400 mg) and diclofenac (0.5 mg, 5 mg and
50 mg). After every dose the patient was assessed and
the OPT was stopped when an objective clinical reaction
occurred – i.e. urticaria, angioedema, asthma, rhinocon-
junctivitis or anaphylaxis. When symptoms were suggest-
ive of hypersensitivity but without objective findings, the
previous dosage was either repeated or the following dos-
age lowered. This accounts for the variation in threshold
dosages (Table 1). Patients were observed 2 hours after
the last dosage was given. In patients suffering from
chronic urticaria the disease had to be without spontan-
eous attacks requiring antihistamine for at least one
month before challenge. In all other patients, antihista-
mines and other drugs likely to affect the outcome were
discontinued minimum three days before the OPT. All
patients with a positive OPT were subsequently classified
according to EAACI/ENDA classification system for
NSAID hypersensitivity reactions [11] and to a recent
more simple classification system [16].
Statistics
The questionnaire responses and clinical data were en-
tered into the database by the first author. Statistical
analysis was performed with STATA/SE 11.0 (Stata
Corporation, TX, USA).
Table 1 Threshold dosages for positive OPTs with acetylicsalicylic acid
Threshold dosage (mg) 750* 667.5* 655 500* 185* 155 80* 55* 30 5
Patients n = 30 1 1 18 1 1 3 1 1 2 1
Following dosages were given orally with 30-minute intervals (5 mg, 25 mg, 125 and 500 mg) adding up to a cumulative dosage of 655 mg.
Mean threshold dosage: 485.3 mg.
*Dosage in regime either repeated or lowered during OPT due to subjective complaints from the patient. See Methods.
OPT = oral provocation test.
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A total of 149 patients, 105 women (70.5%) and 44 men
(29.5%) with suspected NSAID hypersensitivity, were
referred to OPT. The mean age was 44.5 years (range
12–80 years).
Patients’ clinical history revealed that ASA and ibu-
profen were the two most common causes of reported
NSAID hypersensitivity reactions comprising 40% and
32% respectively (Table 2). Urticaria/angioedema was
the most frequently reported symptom (51.0%),
whereas reactions exclusively involving the airways i.e.
asthma/rhino-conjunctivitis were rare (7.4%). Not sur-
prisingly, patients often reported symptoms from dif-
ferent organ systems simultaneously with urticaria/
angioedema and asthma/rhinoconjunctivitis being the
predominant symptom complex (23.5%). Anaphylaxis
defined as grade 3–5 reactions according to severity
score proposed by Sampson was reported by 11.4% of
the patients (Table 2).
All patients had a primary titrated oral provocation
with ASA resulting in 30 positive reactions (Figure 1). If
the primary OPT was negative, and ASA not was the
culprit drug, a secondary provocation test was per-
formed. Hence 55 patients did not undergo further
provocation tests whereas 64 patients were challenged
with their culprit NSAID according to case history
(ibuprofen, diclofenac or naproxen). These provoca-
tion tests yielded 9 positive and 55 negative reactions.
Two patients had a history of multiple reactions after
intake of several NSAIDs and underwent provocation
tests with both ibuprofen and diclofenac, both of which
were negative (Figure 2).
In total, OPTs were positive in 39/149 tested patients
(26.2%). The distribution of positive reactions was as fol-
lows: thirty ASA, six diclofenac, two ibuprofen, and one
naproxen. Table 3 presents the relationship between case
history and positive OPTs with respect to type of reaction.
The most common symptom during OPT was urticaria/
angioedema either alone (17 patients, 43.6%) or in com-
bination with respiratory symptoms (15 patients, 38.5%).
Respiratory symptoms as a solitary sign were seen in 5 pa-
tients (12.8%). Anaphylaxis was observed in 2 patients
(5.1%) both of whom during testing with diclofenac. A
high degree of concordance was found when comparing
the symptoms of the primary reaction with the symptoms
of the OPT with 67% of cases having full concordance and
23% having partial concordance (Table 3).The threshold dosage for eliciting a positive reaction
during OPT for ASA is presented in Table 1. Mean
threshold among the 30 positive ASA was 485.3 mg.
High cumulative dosages were also needed to elicit posi-
tive reactions in OPTs with naproxen (655 mg), ibupro-
fen (570 mg) and diclofenac (36.8 mg).
Our questionnaire was sent to 147/149 patients; 2 pa-
tients had died between their diagnostic work-up and
data collection. The response rate was 81% (119 pa-
tients). Of the 39 patients with a positive OPT, 32
replied.
Based on the positive OPTs and our knowledge of the
patients’ underlying diseases collected from the ques-
tionnaire and medical records we were able to classify
all but one patient according to the EAACI/ENDA
guidelines (Table 4) and to the classification system pub-
lished by Caimmi et al. (Table 5). Using the EAACI/
ENDA guidelines 4 patients in the NERD group also had
cutaneous symptoms and in the NECD and NIUA group
11 patients also had respiratory symptoms.
Discussion
Value of the clinical history
Diagnosing NSAID hypersensitivity is challenging. As
proposed in the revised EAACI/ENDA guideline [12] a
detailed clinical history with regards to previous hyper-
sensitivity reaction(s) and underlying diseases is essential
when planning the diagnostic work-up.
The value of the clinical history to establish the diag-
nosis of NSAID hypersensitivity remains, however, con-
troversial. In a recent study by Blanca-Lopez et al. [17],
oral provocation tests confirmed the diagnosis of mul-
tiple NSAID-triggered urticaria/angioedema in 92% of
cases when more than two NSAIDs were involved in the
clinical history. Dursun et al. [18] also showed good con-
cordance between patient history and results of OPTs in
243 patients with varying severity of asthma. A total of
86% of the patients with a clinical history of NSAIDs-
exacerbated respiratory disease (NERD) had a positive
OPT. The impressive results in both studies were reached
analysing selected patient populations. The patient popu-
lation in our study was more diverse and only 18 patients
(12%) had a history of multiple NSAIDs eliciting hyper-
sensitivity reactions (Table 2). This might explain why our
results differ considerably from those above. Only 39/149
patients (26.2%) had a positive OPT despite having a rele-
vant clinical history. Previous studies with unselected
Table 2 Symptoms and reported eliciting drug(s) based on case history of patients suspected of NSAID hypersensitivity
Symptoms
Patients






n = 11 (7.4%)
Urticaria/ angioedema+
asthma/ rhino- conjunctivitis







Non-urticaria rash + asthma/
rhino-conjunctivitis
n = 3 (2.0%)
Other Nasal
polyposis
n = 1 (0.7%)
Suspected drug Acetylsalicylic acid 59 (40) 33 5 12 5 3 - 1
Ibuprofen 48 (32) 26 2 8 8 2 2 -
Diclofenac 20 (13) 6 1 7 4 1 1 -
Mulitple NSAIDs 18 (12) 9 3 6 - - - -
Naproxen 2 (1,5) 1 - 1 - - - -












Figure 1 Approach to OPTs in 149 patients suspected of NSAID hypersensitivity. All patients performed a primary OPT with acetylsalicylic
acid. If the primary OPT was negative, and ASA not was the culprit drug, a secondary OPT was performed with the culprit NSAID according to
case history. See Figure 2 for details about the secondary OPT. OPTs = oral provocation tests.
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showed similar concordance rates between patient history
and positive provocation tests, 13.8% and 22.2% respect-
ively. Our findings confirm that OPT is the most reliable
method to establish the diagnosis of NSAID hypersensitiv-
ity in an unselected patient population [11,21].
Recent work by our research group revealed a high
correlation between case histories and reactions elicited
during OPTs in patients with penicillin allergy [22]. In
the present study, the confirmed NSAID hypersensi-
tive patients also showed a high degree of correlation
between case history and reactions upon OPTs
(Table 3). Although the case history is not reliable
when diagnosing NSAID hypersensitivity, the caseFigure 2 Results of secondary oral provocation test (OPT) with culprit
challenge for ASA. Nine patients had a positive secondary OPT. *Two patie
and underwent provocation tests with ibuprofen and diclofenac, both of whistory might predict the pattern of response in actual
NSAID responders.
All patients in our cohort underwent OPT regardless
of the severity of their clinical history. This included 17
patients with a clinical history of anaphylaxis (Table 2).
Subsequently, only two patients had a positive reaction
upon OPT none of which were anaphylaxis (Table 3).
This suggests that the severity of the clinical history is
not a reliable predictive factor for possible NSAID
hypersensitivity and that OPTs can be safely performed
in these patients. However, as described in the European
and American guidelines for aspirin provocation tests,
caution and proper anaphylaxis surveillance is imperative
when performing OPTs [21,23]. None of our patients hadNSAID. Sixty-six OPTs were performed in 64 patients with a negative
nts had a history of multiple reactions after intake of several NSAIDs
hich were negative. OPTs = oral provocation tests.











Urticaria/angioedema n = 17 13a 3b 1
Asthma/rhinoconjunctivitis n = 5 5a
Urticaria/angioedema + Asthma/
rhino-conjunctivitis n = 15
6b 8a 1
Anaphylaxis n = 2 2
aIndicate concordance between case history and oral provocation test. bIndicate partial concordance between case history and OPT.
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contraindication of an OPT.
NSAIDs involved
It has been debated whether patterns of consumption of
NSAIDs are reflected in the prevalence of hypersensitiv-
ity reactions. A retrospective study by Dona et al. [24]
involving 659 patients with NSAID hypersensitivity
showed that the NSAIDs most likely to cause a hyper-
sensitivity reaction changed over the course of three de-
cades. Between 1980–1990 pyrazolones and ASA were
the most frequent drugs involved in reactions. In the
period from 1991–2000, ASA was the most frequent and
reactions due to pyrazolones declined. Between 2001–
2010 consumption of propionic acid derivatives such as
ibuprofen increased dramatically and became the most
frequent cause of NSAID hypersensitivity followed by
ASA. Caimmi et al. [16] investigated 980 patients be-
tween 1998 and 2008 who were referred with NSAID
hypersensitivity. The most common NSAIDs involved in
the referrals were ASA (39%) and ibuprofen (15%). The
patients in our cohort were examined from 2002 to
2011. Table 2 shows that ASA (40%), ibuprofen (32%)
and diclofenac (13%) were the three most frequent in-
criminated causes of hypersensitivity reactions. No pa-
tients had a history of reactions to pyrazolones. A
nationwide Danish study that investigated the pattern of
use of NSAID in 4.6 million people between 1997 and
2005 [25], supports that there is a connection between
consumption patterns of NSAID-classes and number of
hypersensitivity reactions. The study investigated the
amount of claimed prescriptions for NSAIDs (minus
ASA). Ibuprofen and diclofenac were by far the two
most frequently used NSAIDs in Denmark. Hardly any
pyrazolones were used explaining the lack of referrals in-
criminating these drugs.
Threshold dosages
When performing OPTs it is recommended that the cu-
mulative dose should be at least the same level as the
therapeutic dose [23]. The most recent EAACI/GA2LEN
guideline on aspirin provocation tests recommend acumulative dose of 500 mg when suspecting NSAIDs-
exacerbated respiratory disease (NERD) and cumulative
dose of 1000 mg when suspecting NSAIDs-exacerbated
cutaneous disease (NECD) and multiple NSAIDs-induced
urticaria/angioedema (NIUA) [21] Our OPT regime for
ASA operates with a cumulative dose of 655 mg and our
results support the use of high cumulative doses when
performing OPTs (Table 1). The mean threshold dose for
eliciting a hypersensitivity reaction upon OPT with ASA
in 30 reactors was 483,5 mg. Recently Blanca-Lopez re-
ported similar results in 57 positive ASA provocation tests
with a median cumulative dose of 300 mg [17]. The cu-
mulative dose of only 655 mg was a limitation in our
study, however, our protocol was performed before the
publication of the EAACI guidelines.
Classification of OPT-positive patients
We succeeded in classifying 38/39 patients with proven
NSAID hypersensitivity according to the EAACI/ ENDA
classification (Table 4). The basis of this classification
system is thorough knowledge of the clinical history and
underlying diseases combined with the results of a posi-
tive OPT. The main challenge classifying the patients
was collection of data concerning underlying diseases.
Without data from our questionnaire, classification
would not have been possible for all patients.
Still, classification was no simple task. Coexistence of
cutaneous and airway symptoms in all three cross-
reactive groups made classification a challenge. Four
patients classified as NSAIDs-exacerbated respiratory
disease (NERD) also had cutaneous symptoms upon
OPT. However, as Samter acknowledged in his original
work, NERD patients frequently also react with skin
symptoms [26]. Similar findings were seen in the
patients classified with NSAIDs-exacerbated cutaneous
disease (NECD) and multiple NSAIDs-induced urticaria/
angioedema (NIUA). In both of these two groups re-
spiratory symptoms were often present concurrently
with urticaria/angioedema (11 patients). Thus in total
15/39 (38.4%) in the three cross-reactive groups both
had cutaneous and respiratory symptoms. The EAACI/
ENDA-guideline and numerous other publications have
Table 4 Characteristics of 39 patients with positive OPT according to the EAACI/ENDA classification [12]












Acute (usually immediate to




















angioedema and anaphylaxis (SNIUAA)
Wheals/angioedema/anaphylaxis No underlying chronic
diseases
Single drug induced Allergic IgE-mediated 9
Single-NSAID-induced delayed
reactions (SNIDR)
Various symptoms and organs
involved (e.g., fixed drug eruption,
SJS/TEN, nephritis)
Delayed onset (usually more





















Table 5 Characteristics of 39 patients with positive OPTs according to the Caimmi classification [16]
Time of reaction Clinical manifestation Type of reaction Underlying disease Putative mechanism Patients n = 38*












disease or atopy or
rhinoconjunctivitis
Unknown, presumably




Single drug induced Atopy or food allergy
or drug allergy
IgE-mediated 9












Usually no T-cell mediated (type IV)
Cytotoxic T cells NK cells
Other
0
*1 patient could not be classified.
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tively rare [10,24,27,28]. Our results suggest that an
overlap in symptoms may be more common than previ-
ously expected, and one can argue that the nomencla-
ture of the cross-reactive immediate reactions i.e. NERD,
NECD and NIUA can be misleading because symptoms
from different organ systems can occur simultaneously.
Another challenging aspect classifying our patients
was the coexistence of chronic urticaria and underlying
respiratory disease. In our cohort 4 patients with
chronic urticaria also suffered from nasal polyposis.
Although this association is well described [24,29,30] it
posed the following question: Should these patients be
classified as NERD or NECD? We chose the latter
based on the predominant urticarial reactions upon
OPT.
Recently, Caimmi et al. addressed the problems with
overlapping clinical manifestations and coexistence of
underlying diseases when classifying 122 provocation
positive patients according to the EAACI/ENDA-guide-
lines in a similar retrospective investigation [16]. Their
solution was to create a new classification system with
only three groups of immediate reactions opposed to
four groups in the EAACI/ENDA-classification (Table 5).
The NERD and NECD-groups were conjugated creating
a common group for patients with underlying diseases.
This puts less emphasis on the clinical manifestation of
the hypersensitivity reaction. Joining the groups is pos-
sible because the putative mechanism of these groups is
thought to be the same. Classifying our patients accord-
ing to this system was easier although this system also
had limitations. Hence we were unable to classify one
patient in either of the classification systems. This pa-
tient was a child with no underlying diseases and a clin-
ical history of urticaria in relation to her first ASA
intake. OPT with ASA was positive and she was not
tested with another NSAID. We could not establish ifher reaction should be classified as multiple NSAID-
induced urticaria/angioedema or as a single NSAID-
induced reaction.
Research has shown that up to 30% of NSAID
hypersensitivity reactions are selective [10,16,20,24].
In our study 9/39 (23.1%) could be classified as single
NSAID induced urticaria/angioedema and anaphylaxis
(SNIUAA). All patients had their hypersensitivity re-
action to the culprit drug after an initial negative
OPT with ASA. Diclofenac was the most common
drug to cause reactions comprising 6 cases (66.7%).
This prevalence is much higher than earlier reports
[10,24]. Whether our findings reflect a higher degree
of selective hypersensitivity to diclofenac than other
NSAIDs is difficult to conclude based on the limited
number of participants in this study. It might rather
reflect regional differences in consumption of various
NSAIDs worldwide. In Denmark, diclofenac is the
second most prescribed NSAID [25]. The majority of
literature about selective NSAID hypersensitivity con-
sists of case reports so more studies are necessary be-
fore conclusions can be made. The only two cases of
anaphylaxis in our cohort came after OPTs with
diclofenac. This higher tendency of anaphylactic reac-
tions among selective NSAID responders has previ-
ously been reported [8,31]. In our study no patients
reacted to pyrazolone drugs. This is important be-
cause the notion that the putative mechanism behind
single drug reactors is allergic primarily comes from
observations on pyrazolones [11,12]. Using the defin-
ition for single drug reactors in the EAACI guidelines
we found 9 patients with a positive reaction to a sin-
gle NSAID (6 diclofenac, 2 ibuprofen, 1 naproxen)
after a negative OPT with ASA. These reactions to
non-pyrazolones would be suspected to be of non-
allergic nature and the conclusion that single reac-
tions to NSAIDs are of an allergic nature should
Nissen et al. Clinical and Translational Allergy  (2015) 5:10 Page 9 of 10therefore be taken very carefully in our patient
cohort.
Main limitations of this study
It is a retrospective study where data was collected from
medical records over a long time-period of 10 years. We
performed open provocation tests, which most guide-
lines do not recommend. For some patients, knowledge
of underlying diseases such as asthma, nasal polyposis
and CRS were based on a questionnaire, which is not
optimal. Finally, in chronic urticaria it is well known that
interpreting positive OPTs is difficult due to the risk of
false positive results.
Conclusions
This study underlines the importance of performing
an OPT when establishing the diagnosis NSAID-
hypersensitivity. The clinical history itself is not suffi-
cient in an unselected patient cohort. However, the
clinical history is important for numerous reasons.
First of all, planning which OPTs should be performed
is based on previous reactions to NSAIDs. Secondly,
classifying NSAID-hypersensitive patients after a positive
OPT is impossible without a detailed clinical history. It is
a key feature that most hypersensitive patients suffer from
underlying diseases such as asthma, CRS, nasal polyposis
and chronic urticaria. The EACCI 2013 guideline recom-
mend performing a challenge test with the culprit drug (if
equivocal history) or to go directly to a challenge test with
aspirin to exclude cross-reactivity. We performed a chal-
lenge test with aspirin directly to exclude cross-reactivity
and found this approach partly helpful. However, the dis-
tinction between cross-reactors and single reactors was
not easy when performing provocation tests with ASA
and the culprit drug (if ASA was negative) only. Further-
more, overlaps in symptoms were common in the patients
rendering classification within this system difficult.
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